Silence Therapeutics (SLN) has released an update.
Silence Therapeutics reports a breakthrough as its phase 2 study of zerlasiran shows substantial and sustained reductions in Lp(a), a key cardiovascular disease risk factor, paving the way for phase 3 trials. The medication, which uses siRNA technology to lower Lp(a) levels, was well received by patients and demonstrated a median reduction of approximately 90% without serious safety concerns. This development offers hope for addressing a significant unmet medical need in cardiovascular health.
For further insights into SLN stock, check out TipRanks’ Stock Analysis page.
